💡 Quick answer
The landmark clinical studies, treatment history and latest research for Latest Hair-Loss Research & Pipeline — fact-checked and sourced.
Research & evidence
How treatment evolved
1988FDA approves topical minoxidil 2% (Rogaine, Upjohn) on Aug 17, 1988 — the first drug approved in the U.S. for androgenetic alopecia; extended to women in 1991 and granted OTC status in 1996.
1997FDA approves oral finasteride 1 mg (Propecia, Merck) on Dec 19, 1997 — the first 5-alpha-reductase inhibitor approved for male pattern hair loss, establishing DHT suppression as a core mechanism.
2022FDA approves baricitinib (Olumiant, Lilly/Incyte) in June 2022 — the first oral systemic drug approved for severe alopecia areata, validating JAK inhibition as a novel mechanism for autoimmune hair loss.
2024Kintor's GT20029, a first-in-class topical PROTAC androgen-receptor degrader, meets its primary endpoint in a China Phase 2 trial for male AGA (announced April 2024), advancing toward Phase 3.
2025Pelage Pharmaceuticals reports positive Phase 2a topline for PP405 (June 2025), a topical hair-follicle-stem-cell activator (MPC inhibitor), and Cosmo reports positive Phase 3 SCALP topline for clascoterone 5% topical (Dec 2025).
Key clinical studies
Kaufman et al. (PFITSG), 19981998
Pivotal pooled Phase 3 RCTs; 1,553 men (vertex studies), 18-41 yr, 2-year double-blind placebo-controlled
Finasteride 1 mg/day produced significant scalp-hair regrowth and halted progression: vertex hair count rose vs continued decline on placebo, with ~48% of treated men improved and ~83% having no further visible loss at 2 years; the landmark efficacy/safety dataset behind FDA approval.
Journal of the American Academy of Dermatology (JAAD)
BRAVE-AA1 & BRAVE-AA2 (King et al.), 20222022
Two pivotal Phase 3 RCTs, 1,200 adults total with severe alopecia areata (>=50% scalp loss), 36 weeks
Baricitinib 4 mg/day achieved a SALT score <=20 (>=80% scalp coverage) in roughly 35-39% of patients vs 3-6% on placebo at week 36 — the registration trials supporting the first FDA-approved systemic therapy for alopecia areata.
New England Journal of Medicine (NEJM)
Gupta et al., 2022 (network meta-analysis)2022
Bayesian network meta-analysis of monotherapies for male androgenetic alopecia (~21 RCTs plus 2 single-arm observational studies, ~15 distinct regimens; some summaries report 33 RCTs/18 interventions/1 control)
Dutasteride 0.5 mg/day ranked the most effective monotherapy for total hair count at 24 weeks (SUCRA ~96%), significantly outperforming finasteride 1 mg and minoxidil; among FDA-approved options, oral finasteride and topical minoxidil 5% ranked highest. Finding is accurately represented.
GT20029 China Phase 2 (Kintor), 2024-20252025
Multicenter, randomized, double-blind, placebo-controlled Phase 2; 180 men with AGA, 6 arms, 12 weeks
Topical PROTAC androgen-receptor degrader met its primary endpoint: GT20029 0.5% once daily increased target-area hair count by ~16.8 hairs/cm2 vs ~10.1 for placebo (p=0.032), with good local tolerability and minimal systemic exposure; first-in-class mechanism now advancing to Phase 3.
Latest research: The 2024-2026 pipeline is shifting beyond DHT suppression toward novel mechanisms: topical androgen-receptor degraders (Kintor's PROTAC GT20029), localized antiandrogens (clascoterone 5%/Breezula, positive Phase 3 SCALP in Dec 2025), and regenerative hair-follicle-stem-cell activation (Pelage's PP405, a mitochondrial-pyruvate-carrier inhibitor with positive Phase 2a in 2025 that reportedly induced new growth from previously empty follicles). Cell-based follicle cloning/dermal-papilla therapy (Epibiotech EPI-001, HairClone) remains preclinical-to-early-trial with no approved product, and Stemson Therapeutics ceased operations in late 2024, underscoring that this branch is still experimental.
Summaries reflect published, peer-reviewed research and are not medical advice. See the linked sources for details.
Explore more
Self-check →Treatments →Transplant →Women →New →Hair Loss Causes →Hair-Loss Glossary →Hair-Loss Questions & Answers →Hair-Loss Ingredient Evidence Ratings →Hair Transplant Cost by City →Research →Browse all →
Not medical advice. General education only; it does not replace diagnosis or treatment by a licensed professional. Consult a board-certified dermatologist before starting, stopping or changing any treatment.
⚠️ When to see a doctor — don’t self-treat
- Sudden patchy or circular bald spots
- Redness, scaling, pus, pain or itch (possible scarring alopecia — treat urgently)
- Broken hairs or rapid loss
- Loss with body-wide signs (weight loss, fatigue, cycle changes, acne, extra hair)
- Loss right after a new medication
- Any hair loss in a child